Registry for patients with rare cancer gene fusions in Europe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to document the real-life management of patients with rare actionable fusions in cancer, focusing on NTRK and other gene mutations. It involves collecting clinical data from medical files and administering a quality of life questionnaire (QLQ-C30) at the time of inclusion, during new treatments, and every six months thereafter. Patients will be followed for at least two years to better understand their treatment outcomes and quality of life. The initiative is a collaborative effort across European centers to enhance data sharing and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with histologically-confirmed cancer
* Patient harboring a rare actionable fusion (see Appendix 1),
* Availability of clinical and demographic data, information on treatment and clinical outcome.
* Adult, ≥18 years old,
* Patient should understand, sign and date the written voluntary informed consent form.

Exclusion Criteria:

-

Where it's running

• Institut Bergonie
  Bordeaux, France Recruiting
• Centre Léon Bérard
  Lyon, France Recruiting
• University Hospital Graz
  Graz, Austria Not yet recruiting
• Medical University of Vienna
  Vienna, Austria Not yet recruiting
• Masaryk Memorial Cancer Institute (Masarykuv Onkologicky Ustav)
  Brno, Czechia Not yet recruiting
• Aarhus University Hospital
  Aarhus, Denmark Not yet recruiting

Study contacts

• Principal investigator: Jean-Yves BLAY, Pr — Centre Leon Berard
• Study coordinator: Julien Bollard
• Email: julien.bollard@lyon.unicancer.fr
• Phone: 04 78 78 28 28

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-22BP mRNA peptide therapy for advanced solid tumors

  A phase 1 study tests a new peptide-delivered IL-22BP mRNA treatment to see if it is safe and if it has any early signs of shrinking or stopping advanced solid tumors in adults.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07583654

• Symptom Management and Survivorship Coaching for Advanced Cancer Patients and Caregivers

  This study tests a 10-week Symptom Management and Survivorship Handbook plus telephone coaching to help metastatic cancer patients and their caregivers manage symptoms and stay connected.

  Recruiting University of Arizona · Tucson, Arizona · NCT07415564

• Comparing two types of radiation therapy for painful bone metastases

  This study is testing whether a new type of radiation therapy can help people with painful bone cancer feel better than the standard treatment.

  Recruiting at 12 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 11 other locations · NCT06391242

• Registry to monitor malnutrition in cancer patients

  This study is trying to see how tracking nutrition in newly diagnosed or treated cancer patients can help improve their health and quality of life.

  Recruiting at 13 sites Fondazione IRCCS Policlinico San Matteo di Pavia · Bari, BA and 15 other locations · NCT06337019

• Peptide vaccine to prevent resistance in advanced lung cancer

  This study is testing a new vaccine to see if it can help people with advanced lung cancer who are on specific treatments avoid or delay their cancer from becoming resistant.

  Recruiting Phase 1/2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT05950139

• Testing the safety and dosing of zeaxanthin for advanced cancer treatment

  This study is testing how much zeaxanthin, a natural compound, can be safely given to people with advanced cancer to see if it helps them without causing bad side effects.

  Recruiting Phase 1 Valley Health System · Paramus, New Jersey · NCT05232409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.